scholarly journals Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome

2021 ◽  
Vol 12 ◽  
Author(s):  
Jason E. Martinez ◽  
Doron D. Kahana ◽  
Simran Ghuman ◽  
Haley P. Wilson ◽  
Julian Wilson ◽  
...  
Keyword(s):  
Fatty Liver Disease ◽  
Intestinal Microbiome ◽  
Unhealthy Lifestyle ◽  
Alcoholic Fatty Liver ◽  
Host Genetics ◽  
Gut Dysbiosis ◽  
Dietary Choices ◽  
Bidirectional Communication ◽  
Habitual Routines ◽  
Alcoholic Fatty Liver Disease

The study of the intestinal or gut microbiome is a newer field that is rapidly gaining attention. Bidirectional communication between gut microbes and the host can impact numerous biological systems regulating immunity and metabolism to either promote or negatively impact the host’s health. Habitual routines, dietary choices, socioeconomic status, education, host genetics, medical care and environmental factors can all contribute to the composition of an individual’s microbiome. A key environmental factor that may cause negative outcomes is the consumption of nicotine products. The effects of nicotine on the host can be exacerbated by poor dietary choices and together can impact the composition of the gut microbiota to promote the development of metabolic disease including non-alcoholic fatty liver disease. This review explores the contribution of nicotine, poor dietary choices and other unhealthy lifestyle factors to gut dysbiosis.

scholarly journals NON-ALCOHOLIC FATTY LIVER DISEASE IN THE CONTEXT OF ALTERED GUT MICROBIOTA

2021 ◽  
Vol 74 (4) ◽  
pp. 1007-1010
Author(s):  
Tetyana V. Koval ◽  
Ivan V. Chopey ◽  
Mykhaylo M. Hechko ◽  
Artur V. Kurakh
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Metabolic Diseases ◽  
Intestinal Microbiome ◽  
Alcoholic Fatty Liver ◽  
Physiological Processes ◽  
The Relationship ◽  
Alcoholic Fatty Liver Disease

The aim: To analyze the relationship between non-alcoholic fatty liver disease and changes in the gut microbiota. Materials and methods: The publications of domestic and foreign editions in the databases of the United European Gastroenterology (UEG) Journal, PubMed, MEDLINE, Web of Science were processed and analyzed. Conclusions: In recent years, non-alcoholic fatty liver disease was placed among the important diseases in gastroenterology. During this time, more and more data appear on the link between changes in the human intestinal microbiome and the development of metabolic diseases, including NAFLD. Contemporary research has indeed found evidence of such a relationship. Thus, some strains of microorganisms have been identified in more detail, which directly or indirectly affect the development or course of the above-mentioned disease. For a better understanding of the strategies for the treatment of pathologies, it is necessary to delve into the study of etiological factors, therefore, NAFLC cannot be considered a pathology that has been sufficiently studied. Indeed, recent data indicate that the development and severity of the course of the disease are not always associated with the physiological processes already known to us.

scholarly journals Perspective strategies for non-alcoholic fatty liver disease therapy: from trial to practice

2020 ◽  
Vol 1 (10) ◽  
pp. 18-25
Author(s):  
I. G. Bakulin ◽  
L. N. Belousova ◽  
L. I. Nazarenko ◽  
A. G. Sushilova
Keyword(s):  
Clinical Trials ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Randomized Clinical Trials ◽  
Intestinal Microbiome ◽  
Good Effect ◽  
Growth Trend ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is the most common diseases all over the world, but there is no so much approved medicines treating liver fibrosis, which is a predictor of total and hepatic mortality in this group of patients. Innovation methods of treating the NAFLD/NASH include several ways: decrease fat accumulation in the liver; influence on oxidative stress; inflammation and apoptosis; impact on the intestinal microbiome and metabolic endotoxemia; antifibrotic drugs. A few drugs which have recommended to use in treating other diseases (for example GLP-1RA for diabetes), demonstrated the good effect of treating NAFLD in clinical trials. There is a big number of drugs from different pharmacological groups, which are on the second and third stage of international multicenter randomized clinical trials, reviewed in this article. Probably, versions of treating NAFLD, which will reduce the growth trend of NAFLD-associated diseases, will be proposed in the near future.

scholarly journals Disbiotic changes in patients with non-alcoholic fatty liver disease

2020 ◽  
Vol 4 (38) ◽  
pp. 44-47
Author(s):  
E. S. Sirchak ◽  
V. I. Griga ◽  
Yo. I. Pichkar ◽  
N. Yu. Kurchak
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Total Cholesterol ◽  
Fatty Liver Disease ◽  
Intestinal Microbiome ◽  
Alcoholic Fatty Liver ◽  
High Incidence ◽  
Grade Ii ◽  
The Relationship ◽  
Alcoholic Fatty Liver Disease

The results of study at 96 patients with non-alcoholic fatty liver disease are presented. A high incidence of intestinal microbiome disorders was observed in the examined patients, especially at the stage of non-alcoholic steatohepatitis. The relationship between the persistence of impaired lipid metabolism and the degree of dysbiosis of the colon, namely between grade II dysbiosis and the level of total cholesterol in patients with non-alcoholic fatty hepatosis (r = 0.77; p < 0.01), and grade III dysbiosis and total cholesterol, triglycerides in patients with non-alcoholic fatty steatohepatitis.

Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease

2020 ◽  
Vol 40 (11) ◽  
pp. 2719-2731
Author(s):  
Xinrong Zhang ◽  
George B.‐B. Goh ◽  
Wah‐Kheong Chan ◽  
Grace L.‐H. Wong ◽  
Jian‐Gao Fan ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Physical Inactivity ◽  
Unhealthy Lifestyle ◽  
Lifestyle Habits ◽  
Alcoholic Fatty Liver ◽  
Asian Patients ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document